Thailand is both a donor and implementer of Global Fund programmes. Since 2001, Thailand has contributed a total of US$ 23.34 million to date, and at the Sixth Replenishment, pledged US$ 4.5 million. 

Since 2004, the Global Fund has disbursed over US$ 545.59 million to Thailand for HIV, TB, TB/HIV and malaria programmes, and Thailand is included in the following multicountry grants of the Global Fund – Multicountry Asia IHAA, Multicountry East Asia and Pacific APN, Multicountry East Asia and Pacific RAI, Multicountry South-Eastern Asia AFAO, and Multicountry TB Asia TEAM.

In April 2019, the Dhanin Tawee Chearavanont Foundation became the first private sector partner to support the Global Fund’s largest regional initiative to eliminate drug-resistant malaria in the Greater Mekong region with a contribution of US$ 2 million over two years. 

Through the COVID-19 Response Mechanism (C19RM) in 2021, the Global Fund supported Thailand with over US$ 20.6 million to fight COVID-19, including for the procurement of personal protective equipment (PPE) and COVID-19 diagnostic tests, strengthening  infection prevention and control, and the procurement of TB molecular test equipment with strong focus on provision for community organisations, migrants and key population. The C19RM funding also focused on mitigating the impact of COVID-19 on HIV and TB programmes and strengthening community health systems (including community-led monitoring, social mobilisation and advocacy, and community-based organisation institutional strengthening). 

In the 2020-2022 allocation cycle of the Global Fund, 17.8% of the total resources raised during the Sixth Replenishment have been allocated for the East Asia and the Pacific and the South Asia regions which constitute the Asia-Pacific region.

As of 2019, the Global Fund has saved 18.7 million lives in the region, has put 2.3 million people on antiretroviral therapy for HIV, has treated 4.2 million people with TB and has distributed 25 million mosquito nets.18.7 million lives saved through the Global Fund partnership represents 49% of the global figure; 2.3 million people on antiretroviral therapy  represent 11% of the global figure; 4.2 million people with TB treated represents 73% of the global figure; and 25 million mosquito nets distributed is 16% of the global figure. (please note that these numbers include Asia -Pacific and MENA 2 regions.  Asia and the Pacific includes countries in South West Asia, East Asia, and the Pacific. MENA 2 comprises Iraq, Jordan, Lebanon, Palestine, Syria, and Yemen).

Progress towards 2030 HIV targets in Asia-Pacific is mixed with Cambodia and Thailand have achieved targets, but many other countries off track. Overall there was a 12% reduction in new infections and a 29% reduction in deaths from 2010 – 2019. In 2019 South-East Asia (SEA) had the largest global share of people with TB (44%). Western Pacific (WP) had the third largest (18%). Incidence reduction was 8.7% in SEA and 6.1% in WP from 2010- 2019, deaths declined 10% and 17% respectively. Reduction in malaria  incidence (73%) and deaths (74%) in South-East Asia (SEA) is the highest of any region between 2000-2019. All countries in SEA were on track to achieve the Global Technical Strategy for Malaria Elimination  2020 targets, except Indonesia with a 37% mortality reduction. The Western Pacific (WP) region has seen a 5% increase in incidence and 10% reduction in deaths since 2010.